TREMFYA® Infusion Therapy

Download Referral Form

About TREMFYA® Infusion Therapy

TREMFYA® (guselkumab) is a prescription medication that belongs to a class of drugs called interleukin inhibitors. It was the first medication of its kind to be approved by the Food and Drug Administration (FDA) in 2017 for treating adults with moderate to severe plaque psoriasis. Tremfya is a biologic medication, specifically a monoclonal antibody. It works by blocking a protein called interleukin-23 (IL-23) in your body, which normally activates your immune system.

Condition treated by this therapy

TREMFYA® is a biologic medication for the treatment of:

Moderate to severe plaque psoriasis
- In adults who are candidates for systemic therapy or phototherapy (light treatment).
- In two clincal studies, at least 7 out of 10 patients saw at lease 90% clearer skin at 16 weeks using TREMFYA®.
Active psoriatic arthritis
- In clincial studies, more than 5 out of 10 patients treated with TREMFYA® had at least 20% improvement in active psoriatic arthritis symptoms at 24 weeks compared to placebo.
Moderate to severely active ulcerative colitis (UC) in adults
Moderate to severely active Crohn's disease in adults

TREMFYA® lowers inflammation (swelling) in your body to treat symptoms of these diseases.

TREMFYA® Price

The out-of-pocket TREMFYA® price will vary depending on your insurance coverage. If you have questions about your coverage, contact your insurance provider.

TREMFYA® withMe is a support program for patients on TremfyaYour healthcare team can provide information about patient assistance programs that may help with costs

No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.

What to Expect During TREMFYA® Infusion Therapy

TREMFYA® is available in the following forms:

Single-dose prefilled syringe: 100 milligrams per milliliter (mg/mL) and 200 mg/2 mL
Patient-controlled injector (One-Press)
Single-dose vial in a strength of 200 mg/20 mL (10 mg/mL) for intravenous (IV) infusion (used only for UC at the start of treatment)

Method of administering and treatment is dependent on disease being treated. Ask your healthcare provider for more details on your specific treatment plan.

TREMFYA® Side Effects

Although rare, serious side effects may include:

Infections
- Tremfya lowers the ability of your immune system to fight infections and can increase the risk of infections, including tuberculosis.
Allergic Reactions
- TREMFYA® may cause allergic reactions, which can be serious.
- Seek immediate medical attention if you experience severe allergic reaction symptoms.
Liver Damage
- Liver damage, also called hepatotoxicity, can happen when using TREMFYA®.
- In patients with Crohn disease or ulcerative colitis, evaluate liver enzymes and bilirubin at baseline, for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.

Before starting treatment with TREMFYA®, your doctor may perform tests to make sure you do not have tuberculosis or other infections. Make sure you are current on all vaccines before you start treatment with TREMFYA®. Do not receive a "live" vaccine while using TREMFYA®. The vaccine may not work as well and may not fully protect you from disease.

TREMFYA® Therapy at Violet Health

Your comfort during TREMFYA® infusion therapy at Violet Health is our priority. Our TREMFYA® patients enjoy walk-up parking, complimentary entertainment and snacks, and a team of highly trained providers during each treatment. Plus, Violet Health’s evening and weekend hours and convenient city and rural locations make it easier to schedule your appointments.

Violet Health Infusion Centers provides infusion therapy for patients with rare, chronic, or complex conditions in a comfortable, patient-centered atmosphere.

Find Infusion Center Near You!

Helpful Resources

Patient Forms

Before you attend your first appointment at Violet Health, please make sure to review the documents below. Please contact us if you have any questions!